0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
RSS Email Alerts
Please Wait... Processing your request... Please Wait.

Original Investigation |  FREE
Joanne Thompson, MB, MRCP; Marvin Reid, MB,BS, PhD; Ian Hambleton, PhD, BA, MSc; et al.
Arch Intern Med. 2007;167(7):701-708. doi:10.1001/archinte.167.7.701.

Editor's Correspondence | 
Alexandros C. Makis, MD, PhD; Eleftheria C. Hatzimichael, MD; Justin Stebbing, MD, MRCP, PhD; et al.
Arch Intern Med. 2006;166(3):366-368. doi:10.1001/archinte.166.3.366.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Subscribe to the journal
From The JAMA Network
JAMA
Editorial  | 
Reconsideration of Age as a Contraindication for Curative Therapy of Sickle Cell Disease
Allison A. King, MD, MPH; John F. DiPersio, MD, PhD
JAMA
Original Investigation  | 
Nonmyeloablative HLA-Matched Sibling Allogeneic Hematopoietic Stem Cell Transplantation for Severe Sickle Cell Phenotype
Matthew M. Hsieh, MD; Courtney D. Fitzhugh, MD; R. Patrick Weitzel, PhD; et al.
JAMA
Viewpoint  | 
Sickle Cell Trait—Neglected Opportunities in the Era of Genomic Medicine
Catherine Taylor, MB, BChir; Patricia Kavanagh, MD; Barry Zuckerman, MD
JAMA Ophthalmology
Case Report/Case Series  | 
Acute, Bilateral, Concurrent Central Retinal Artery Occlusion in Sickle Cell Disease After Use of Tadalafil (Cialis)
Ravi K. Murthy, MD; Lizette Perez, MD; Joshua C. Priluck, MD; et al.